The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials

(2022) Corinne Frere et al.   Journal of Hematology & Oncology

Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer

(2022) Tzu-Fei Wang   THROMBOSIS RESEARCH

Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors

(2022) Tzu-Fei Wang et al.   JAMA Network Open

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

(2021) Gary H. Lyman et al.   Blood Advances

Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

(2021) Tzu‐Fei Wang et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism

(2021) Benjamin Planquette et al.   CHEST

Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population‐based nested case–control study

(2020) Yumao Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prospective evaluation of drug–drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation

(2020) Hank K Ng et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

(2020) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin

(2020) Sandip H. Patel et al.   CANCER

Venous thromboembolism in cancer patients: a population-based cohort study

(2020) F. I. Mulder et al.   BLOOD

Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer

(2019) Alexander Hoemme et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

(2019) Robert D. McBane et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

(2018) Annie M. Young et al.   JOURNAL OF CLINICAL ONCOLOGY

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-drug interactions of non-vitamin K oral anticoagulants

(2016) Christos Voukalis et al.   Expert Opinion on Drug Metabolism & Toxicology

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs

(2013) R W F van Leeuwen et al.   BRITISH JOURNAL OF CANCER

Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function

(2011) Francisco J. de Abajo   DRUGS & AGING

Potential drug interactions in elderly cancer patients

(2010) V. Girre et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Medication Problems in Older, Newly Diagnosed Cancer Patients in Canada: How Common are They?

(2009) Martine T.E. Puts et al.   DRUGS & AGING

Potential Drug Interactions in Cancer Patients Receiving Supportive Care Exclusively

(2008) Rachel P. Riechelmann et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT